LouisBNaborsIIIMD

Neurology • Birmingham, AL

Neurooncology

Professor, Neurology, University of Alabama at Birmingham School of Medicine

Join to view full profile

Dr. Nabors is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nabors' full profile

Already have an account?

Office
1717 6th Ave S
Birmingham, AL 35233
Phone+1 800-822-8816

Fax+1 205-975-7546

Summary

Director, Neuro-Oncology

Education & Training

University of Alabama Medical CenterResidency, Neurology, 1995 - 1998
National Capital ConsortiumInternship, Internal Medicine, 1991 - 1992
University of Tennessee Health Science Center College of MedicineClass of 1991

Certifications & Licensure

AL State Medical License 1995 - 2025
FL State Medical License 1994 - 1996
American Board of Psychiatry and Neurology Neurology

Clinical Trials

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Start of enrollment: 2000 Sep 01
Completed
Phase 1, Phase 2
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2005 Apr 01
Completed
Phase 1, Phase 2
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma Start of enrollment: 2004 Dec 01
Completed
Phase 1
A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2003 Aug 01
Completed
Phase 1
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2009 Jul 13
Completed
Phase 1
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status Start of enrollment: 2009 Mar 01
Completed
Phase 2
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Jul 01
Completed
Phase 2
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma Start of enrollment: 2012 Jan 01
Completed
Not Applicable
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients Start of enrollment: 2011 Apr 01
Completed
Early Phase 1
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma Start of enrollment: 2013 Aug 01
Suspended
Phase 1, Phase 2
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma.
Eudocia Q Lee, Brian M Alexander, Carlos G Romo, Jeffrey G Supko, Nathalie Y R Agar
Clinical Cancer Research. 2025-01-17
Pilot Screening of TREM1 Inhibitors in Cell-Based Reporter Assays Reflecting TREM1/DAP12 Receptor Assembly and Functionality.
Natalia Filippova, Roman Hromov, James Shi, Peter H King, Louis B Nabors
ACS Chemical Neuroscience. 2025-01-01
NCCN CNS Tumor Guidelines Update for 2024.
Louis Burt Nabors, Jona Hattangadi-Gluth, Craig Horbinski, Jana Portnow
Neuro-Oncology. 2024-12-18

Journal Articles

Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma
Louis B Nabors, April Eichler, Clinical Cancer Research